Skip to main content
. 2020 May 8;22(9):1568–1581. doi: 10.1002/ejhf.1840

Figure 5.

EJHF-1840-FIG-0005-c

Inhibition of the effects of LAV‐BPIFB4 gene therapy by an antagonist of the CXCR4 receptor. (A) Experimental protocol: seven mice entered the study but only six in each antagonist group were considered because compliant in taking the medicated jelly. All data shown as individual values and means ± SEM. (B–F) Results of echocardiography. The antagonist inhibits the effect of LAV‐BPIFB4 gene therapy on deceleration time (DT) (B), end‐systolic volume (ESV) (C), fractional shortening (FS) (D), left ventricular ejection fraction (LVEF) (E), and cardiac output (CO) (F). *P < 0.05 and **P < 0.01 vs. GFP + DMSO, # P < 0.05 and ## P < 0.01 in comparison with changes between LAV + DMSO and GFP + DMSO. (G) Capillary density (scale bars: 50 μm). Isolectin B4 (green) identifies endothelial cells, α‐smooth muscle actin (red), and DAPI nuclei (blue). Bar graph showing the results. **P < 0.01 vs. GFP + DMSO, ## P < 0.01 in comparison with changes between LAV + DMSO and GFP + DMSO. (H,I) Cardiac interstitial (H) and perivascular (I) fibrosis (blue) analysed by Azan Mallory staining (scale bars: 50 μm). ***P < 0.001 vs. GFP + DMSO, ## P < 0.01 in comparison with changes between LAV + DMSO and GFP + DMSO.